Current Drug Targets

Author(s): Dornadula Sireesh, Elango Bhakkiyalakshmi, Kunka Mohanrama Ramkumar, Shanmugakani Rathinakumar, Panneer Selvam Anto Jennifer, Palanisamy Rajaguru and Ramasamy Paulmurugan

DOI: 10.2174/1389450115666140915124747

DownloadDownload PDF Flyer Cite As
Targeting SUMOylation Cascade for Diabetes Management

Page: [1094 - 1106] Pages: 13

  • * (Excluding Mailing and Handling)

Abstract

Post-translational modifications (PTMs) play important roles in regulating protein stability, trafficking, folding conformation, and functional activity. Small ubiquitin-like modifier (SUMO) protein mediates a distinct type of PTM called SUMOylation in which the SUMO protein is covalently ligated to the target protein and modifies its activities through a series of enzymatically-catalyzed reactions. SUMOylation regulates many cellular processes like transcription, the maintenance of the ion gradient across the cell membrane, stress response, autoimmunity, etc. Several target proteins of SUMOylation are involved in the biological pathways related to various human diseases, including cardiovascular diseases, diabetes, cancer, and neurodegenerative disorders. This review focuses on the SUMOylation process, regulatory roles of SUMOylation in diabetes, and prospects of developing novel anti-diabetic drugs targeting the SUMOylation process.

Keywords: Diabetes, post-translational modification, SUMO inhibitors, SUMO targets, SUMOylation.